177Lu-A9-0631 An investigational lutetium-177 radiotherapeutic targeting GRPR, being evaluated in Phase 1 for breast cancer and other solid tumors.
Visit productCosigns Received
Be the first Cosign
Put your name behind 177Lu-A9-0631.
Add it to your Products I use list and share why you use it.